Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Hervé Ghesquières, Fanny Cherblanc, Aurélien Belot...
https://pubmed.ncbi.nlm.nih.gov/37874913/Actively Recruiting
Led by Hospices Civils de Lyon · Updated on 2021-06-28
6000
Participants Needed
37
Research Sites
N/A
Total Duration
Researchers are studying lymphoma in adults to better understand prognostic factors by combining epidemiological, clinical, and biological data. The study focuses on seven subtypes of lymphoma and aims to identify causes of treatment resistance and relapse, monitor long-term health effects, and assess quality of life and second cancers in survivors. This observational platform also looks at how treatments work in real life and explores socio-economic issues related to lymphoma. Participants diagnosed with lymphoma within the last six months and who consent to join the REALYSA cohort provide data for this study. There is no treatment given as part of this observational study instead, data about the patients lymphoma subtype, treatments received, and outcomes are collected and analyzed over time. Patients are included from various regions and lymphoma subtypes to create a comprehensive database. During the study, researchers collect ongoing information about patients health, treatments, and disease progression. They measure outcomes such as progression-free survival over five years and record events like second cancers and chronic diseases. The study tracks patients response rates, survival, and frequency of lymphoma transformations. Participants are followed long-term to better understand lymphoma outcomes and quality of life.
CONDITIONS
REal World Data in LYmphoma and Survival in Adults
H
Hervé Ghesquières, MD
A
Alain Monnereau, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospices Civils de Lyon
Lead Sponsor
The Lymphoma Academic Research Organisation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 9 years
Participants are observed over several years to collect data on lymphoma progression, survival, and related health outcomes.
Periodic visits as determined by routine care and study protocol
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Hervé Ghesquières, Fanny Cherblanc, Aurélien Belot...
https://pubmed.ncbi.nlm.nih.gov/37874913/Hervé Ghesquières, Cédric Rossi, Fanny Cherblanc...
https://pubmed.ncbi.nlm.nih.gov/33653294/Hospices Civils de Lyon
Lead Sponsor
The Lymphoma Academic Research Organisation
Collaborating Sponsor